Regulation of Vascular Smooth Muscle Cell Proliferation
血管平滑肌细胞增殖的调节
基本信息
- 批准号:7816769
- 负责人:
- 金额:$ 5.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-05-01 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAccountingAddressAmino AcidsAnimal ModelArterial DisorderArterial InjuryBackBindingBlood VesselsCardiovascular DiseasesCause of DeathCell ShapeCell SizeCessation of lifeChronicClinical TrialsComplement component C1sCoronary ArteriosclerosisCoronary arteryDataDevelopmentDiabetes MellitusDiabetic mouseDrug CombinationsEatingEnergy MetabolismEventFamilyFatty AcidsFeedbackFigs - dietaryGTP-Binding ProteinsGene ExpressionGlucoseGrowthHeart TransplantationHomologous GeneHyperglycemiaHyperplasiaIn VitroIncidenceInjuryInsulinInsulin ReceptorLeadLeptinMalignant NeoplasmsMeasuresMediatingMetabolic syndromeMitogen-Activated Protein KinasesModelingMolecular ProbesMusNon-Insulin-Dependent Diabetes MellitusNonesterified Fatty AcidsNutrientObesityOutcomePDPK1 genePTEN genePathway interactionsPeripheral Vascular DiseasesPharmaceutical PreparationsPhosphatidylinositolsPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPlayProtein KinaseProtein Kinase CProteinsProto-Oncogene Proteins c-aktRaptorsRegulationRelative (related person)ResistanceRibosomal Protein S6 KinaseRiskRisk FactorsRoleSerineSeveritiesSignal PathwaySignal TransductionSimulateSirolimusSmooth Muscle MyocytesSomatomedinsStentsSymptomsTacrolimus Binding Protein 1ATacrolimus Binding ProteinsTestingTherapeuticTuberous SclerosisTumor Suppressor ProteinsUnited StatesVascular Diseasescell growthdiabeticdiabetic patientfeedingfemoral arteryglucose uptakehuman diseasein vivoinhibitor/antagonistmTOR proteinmigrationmouse modelnon-diabeticnovelpolypeptidepreventreceptorrestenosistensintranscription factorvascular smooth muscle cell migrationvascular smooth muscle cell proliferation
项目摘要
DESCRIPTION (provided by applicant): Cardiovascular disease accounts for nearly one third of deaths globally, and coronary artery disease remains the number one cause of death in the United States. Diabetes increases the risk of fatal CAD and peripheral vascular disease. Vascular smooth muscle cell (VSMC) proliferation and migration contribute to coronary artery disease and are the major causes of coronary artery in-stent restenosis and accelerated arteriopathy following cardiac transplantation. Drug-eluting stents (rapamycin-sirolimus) was a major advance in the treatment of CAD, causing significant reduction in the incidence of restenosis. However, diabetic patients still had a two-fold higher incidence of restenosis compared to non-diabetics. We will use rapamycin as a "molecular probe" to dissect pathways that govern VSMC growth and migration. Aim one will test the hypothesis that diabetes leads to an overstimulation of the PI3K/Akt/Foxo pathway', decreasing p27Kip1 gene expression, conferring relative rapamycin resistance. We will examine the effects of rapamycin on the proliferation and migration of VSMC grown in the presence of high glucose Jeptin treated, then on the formation of neointimal hyperplasia following arterial injury in different mouse models of diabetes. Aim two will determine whether blocking multiple growth pathways using rapamycin and inhibitors of Akt/PI3K can synergistically inhibit intimal proliferation following vascular injury in diabetic/obesity animal models. We will test new drug combinations in animal model in which resistance to rapamycin's antiproliferative effect was observed.
描述(由申请人提供):心血管疾病占全球死亡人数的近三分之一,而冠状动脉疾病仍然是美国的第一大死因。糖尿病会增加致命性 CAD 和周围血管疾病的风险。血管平滑肌细胞(VSMC)增殖和迁移导致冠状动脉疾病,是心脏移植后冠状动脉支架内再狭窄和加速动脉病变的主要原因。药物洗脱支架(雷帕霉素-西罗莫司)是 CAD 治疗的重大进步,可显着降低再狭窄的发生率。然而,与非糖尿病患者相比,糖尿病患者的再狭窄发生率仍然高出两倍。我们将使用雷帕霉素作为“分子探针”来剖析控制 VSMC 生长和迁移的途径。目标之一将检验糖尿病导致 PI3K/Akt/Foxo 通路过度刺激、降低 p27Kip1 基因表达、赋予相对雷帕霉素耐药性的假设。我们将研究雷帕霉素对高糖杰普汀治疗下生长的 VSMC 增殖和迁移的影响,以及对不同糖尿病小鼠模型动脉损伤后新内膜增生形成的影响。目标二将确定使用雷帕霉素和 Akt/PI3K 抑制剂阻断多种生长途径是否可以协同抑制糖尿病/肥胖动物模型血管损伤后的内膜增殖。我们将在动物模型中测试新的药物组合,在动物模型中观察到对雷帕霉素的抗增殖作用产生耐药性。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MicroRNAs and the cellular response to rapamycin Potential role in diagnosis and therapy
MicroRNA 和细胞对雷帕霉素的反应在诊断和治疗中的潜在作用
- DOI:
- 发表时间:2024-09-14
- 期刊:
- 影响因子:0
- 作者:H. Wu
- 通讯作者:H. Wu
Reprogramming of the microRNA transcriptome mediates resistance to rapamycin.
microRNA 转录组的重编程介导对雷帕霉素的耐药性。
- DOI:
- 发表时间:2013-03-01
- 期刊:
- 影响因子:0
- 作者:Totary;Sanoudou, Despina;Ben;Dautriche, Cula N;Guarnieri, Paolo;Marx, Steven O;Tuschl, Thomas;Marks, Andrew R
- 通讯作者:Marks, Andrew R
Vascular smooth muscle cell proliferation in restenosis.
- DOI:10.1161/circinterventions.110.957332
- 发表时间:2011-02-01
- 期刊:
- 影响因子:0
- 作者:Marx SO;Totary-Jain H;Marks AR
- 通讯作者:Marks AR
Tailoring mTOR-based therapy: molecular evidence and clinical challenges.
- DOI:10.2217/pgs.13.143
- 发表时间:2013-09
- 期刊:
- 影响因子:2.1
- 作者:Santulli G;Totary-Jain H
- 通讯作者:Totary-Jain H
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hana Totary-Jain其他文献
Hana Totary-Jain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hana Totary-Jain', 18)}}的其他基金
Cell-Selective Therapies for Coronary Artery Disease
冠状动脉疾病的细胞选择性疗法
- 批准号:
10543849 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9110298 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9268806 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
Cell-Selective Therapies for Coronary Artery Disease
冠状动脉疾病的细胞选择性疗法
- 批准号:
10323294 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9110298 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9474655 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8838234 - 财政年份:2013
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8788329 - 财政年份:2013
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8306029 - 财政年份:2011
- 资助金额:
$ 5.38万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8306029 - 财政年份:2011
- 资助金额:
$ 5.38万 - 项目类别:
相似国自然基金
套期会计有效性的研究:实证检验及影响机制
- 批准号:72302225
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
上市公司所得税会计信息公开披露的经济后果研究——基于“会计利润与所得税费用调整过程”披露的检验
- 批准号:72372025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
- 批准号:72372064
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
兔死狐悲——会计师事务所同侪CPA死亡的审计经济后果研究
- 批准号:72302197
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332003
- 批准年份:2023
- 资助金额:166 万元
- 项目类别:重点项目
相似海外基金
The Na/K-ATPase receptor function as a novel therapeutic target in myocardial infarction
Na/K-ATP酶受体作为心肌梗死的新型治疗靶点
- 批准号:
9813314 - 财政年份:2019
- 资助金额:
$ 5.38万 - 项目类别:
Functional Dissection of Autophagosome Biogenesis
自噬体生物发生的功能剖析
- 批准号:
8868838 - 财政年份:2015
- 资助金额:
$ 5.38万 - 项目类别:
A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells
静止的 G0 样细胞状态是根除口腔癌干细胞的障碍
- 批准号:
8722223 - 财政年份:2014
- 资助金额:
$ 5.38万 - 项目类别:
A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells
静止的 G0 样细胞状态是根除口腔癌干细胞的障碍
- 批准号:
8722223 - 财政年份:2014
- 资助金额:
$ 5.38万 - 项目类别:
Autophagy in epidermal melanocyte: a protective or a destructive role?
表皮黑素细胞的自噬:保护作用还是破坏作用?
- 批准号:
8496721 - 财政年份:2012
- 资助金额:
$ 5.38万 - 项目类别: